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ABSTRACT Macrolide antibiotics are mainstays in the treatment of lung disease
due to the Mycobacterium abscessus complex. Although previous studies have re-
ported development of acquired macrolide resistance in this species, limited data
are available on the outcomes of lung disease due to macrolide-resistant Mycobacte-
rium abscessus subsp. abscessus. This study evaluated the clinical features, treatment
outcomes, and molecular characteristics of macrolide-resistant isolates of M. absces-
sus subsp. abscessus. We performed a retrospective review of medical records and
genetic analysis of clinical isolates from 13 patients who had acquired macrolide-
resistant M. abscessus subsp. abscessus lung disease between November 2006 and
March 2016. Eleven (85%) patients had the nodular bronchiectatic form of the dis-
ease, and two (15%) patients had the ﬁbrocavitary form. When acquired macrolide
resistance was detected, 10 (77%) patients were on antibiotic therapy for M. absces-
sus subsp. abscessus, and three (23%) patients were on therapy for lung disease due
to other nontuberculous mycobacteria. The median treatment duration after detect-
ing resistance was 24.0 months (interquartile range, 16.0 to 43.0 months). Treatment
outcomes were poor, and ﬁnal sputum culture conversion was achieved in only one
(8%) patient, after resectional surgery. All 13 clinical isolates demonstrated point mu-
tations at position 2058 (n  10) or 2059 (n  3) of the 23S rRNA gene, which re-
sulted in acquired macrolide resistance. This study indicates that treatment out-
comes are very poor after the development of acquired macrolide resistance in patients
with M. abscessus subsp. abscessus lung disease. Thus, more effective measures are
needed to prevent development and effectively treat macrolide-resistant M. abscessus
subsp. abscessus lung disease.
KEYWORDS nontuberculous mycobacteria, Mycobacterium abscessus, macrolides,
drug resistance
The prevalence of pulmonary disease caused by nontuberculous mycobacteria(NTM) is increasing worldwide (1, 2). Mycobacterium abscessus complex is the most
important cause of pulmonary infections by rapidly growing mycobacteria in patients
with chronic lung diseases, such as bronchiectasis and cystic ﬁbrosis (3, 4). Currently,
Mycobacterium abscessus complex can be divided into three subspecies:Mycobacterium
abscessus subsp. abscessus, Mycobacterium abscessus subsp. massiliense, and Mycobac-
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terium abscessus subsp. bolletii (5, 6). Of the three subspecies, M. abscessus subsp.
abscessus is the most common pathogen, followed by M. abscessus subsp. massiliense
and M. abscessus subsp. bolletii (7).
Of the rapidly growing mycobacterial pathogens, M. abscessus subsp. abscessus is
the most difﬁcult to treat because of its intrinsic and acquired multidrug resistance (8),
and antibiotic treatment success rates are less than 50%, in contrast to the high
treatment success rates (80 to 90%) with M. abscessus subsp. massiliense infection
(9–13). Macrolides, such as clarithromycin and azithromycin, are considered the corner-
stone for treatment of M. abscessus subsp. abscessus infections (3). The poor treatment
outcomes in M. abscessus subsp. abscessus lung disease are attributed to inducible mac-
rolide resistance, demonstrated by susceptibility to macrolides at day 3 but resistance at
day 14 of drug susceptibility testing (DST); this type of resistance is conferred by the
ribosomal methyltransferase gene erm(41) (14, 15). In addition to inducible macrolide
resistance, acquired macrolide resistance, demonstrated by resistance to macrolides at day
3 of DST, can develop during macrolide antibiotic treatment due to mutations in the
drug-binding pocket of the 23S rRNA gene (rrl) at nucleotide positions 2058 and 2059
(15, 16).
Although previous studies reported that acquired macrolide resistance developed
in some patients with M. abscessus subsp. abscessus infections during macrolide-
containing antibiotic treatment (17–19), no published data are available regarding
detailed clinical characteristics and treatment outcomes of patients with acquired
macrolide-resistant M. abscessus subsp. abscessus lung disease. The purposes of this
study were to evaluate the clinical features and treatment outcomes of patients with
acquired macrolide-resistantM. abscessus subsp. abscessus lung disease and to examine
the molecular characteristics of their isolates.
RESULTS
Patient characteristics. A total of 13 patients were diagnosed with acquired
macrolide-resistant M. abscessus subsp. abscessus lung disease during the study period.
The clinical characteristics of the patients are summarized in Table 1. For four of the
patients, some clinical data were included in recently published articles (12, 20); data on
the remaining patients have not been previously reported. There were eight (62%)
female patients, and the median age of all patients was 64 years (interquartile range
[IQR], 55 to 78 years). Eight (62%) patients had a history of prior treatment for
pulmonary tuberculosis. Six (46%) patients had a history of previous treatment for NTM
lung disease: four of these patients had Mycobacterium avium complex (MAC) infection,
one patient had M. abscessus subsp. massiliense infection, and one patient had MAC
infection followed by M. abscessus subsp. massiliense infection.
Sputum smears were acid-fast bacillus (AFB) positive for all patients at the time
acquired macrolide resistance was detected. Two (15%) patients had the ﬁbrocavitary
form of lung disease, and 11 (92%) patients had the nodular bronchiectatic form.
Cavitary lesions were found on high-resolution computed tomography (HRCT) for 6
(55%) of 11 patients with the nodular bronchiectatic form.
Antibiotic therapy before detection of acquired macrolide-resistant M. absces-
sus subsp. abscessus. For one (8%) patient, macrolide resistance was detected upon
transfer to our hospital after long-term antibiotic treatment at another hospital. For 12
(92%) patients, macrolide resistance developed during antibiotic treatment at our
institution. All patients received macrolide treatment, and the median duration of
exposure to a macrolide was 19.0 months (IQR, 10.5 to 42.5 months) before detection
of acquired macrolide resistance.
In 10 (77%) patients, macrolide resistance was detected during combined antibiotic
therapy for M. abscessus subsp. abscessus lung disease, which consisted of intravenous
(i.v.) amikacin, i.v. cefoxitin (or imipenem), and an oral macrolide, with or without
ﬂuoroquinolone, doxycycline, and clofazimine. In three (23%) patients, macrolide re-
sistance was detected during antibiotic therapy for other NTM lung diseases: two
patients with MAC infection had received an oral macrolide, rifampin, and ethambutol,
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and one patient with M. abscessus subsp. massiliense infection had received an oral
macrolide, i.v. amikacin, and i.v. cefoxitin (Table 2).
Treatment and outcomes after detection of acquired macrolide-resistant M.
abscessus subsp. abscessus. The treatment regimens after detection of macrolide
resistance and subsequent treatment outcomes are summarized in Table 3. Of 13
patients, two (15%) did not receive antibiotic therapy after detection of macrolide
resistance: one patient had been observed at an outpatient clinic after completing
TABLE 1 Clinical characteristics of patients (n  13) with acquired macrolide-resistant M.
abscessus subsp. abscessus lung disease at diagnosis
Clinical characteristicsa Valueb
Female 8 (62)
Age, years 64 (55–78)
BMI, kg/m2 19.9 (18.2–22.0)
Nonsmoker 11 (85)
Previous treatment for pulmonary tuberculosis 8 (62)
Previous treatment for NTM lung disease 6 (46)
Comorbidities
COPD 1 (8)
Bronchiectasis 12 (92)
Chronic pulmonary aspergillosis 1 (8)
Chronic heart disease 1 (8)
Laboratory ﬁndings
Positive sputum AFB smear 13 (100)
ESR, mm/h 39 (13–102)
CRP, mg/dl 0.3 (0.1–1.6)
Radiologic ﬁndings
Fibrocavitary form 2 (15)
Nodular bronchiectatic form 11 (85)
With cavity 6
Without cavity 5
Pulmonary function test
FVC, liters 2.33 (1.94–3.30)
FVC, % predicted 75 (61–91)
FEV1, liters 1.85 (1.31–2.56)
FEV1, % predicted 80 (57–92)
aAbbreviations: BMI, body mass index; NTM, nontuberculous mycobacteria; COPD, chronic obstructive
pulmonary disease; AFB, acid-fast bacilli; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; FVC,
forced vital capacity; FEV1, forced expiratory volume in 1 s.
bData are presented as number (percentage of total) or as median (interquartile range).
TABLE 2 Treatment regimens before detection of macrolide-resistant M. abscessus subsp.
abscessus lung diseasea,b
Treatment regimen Value
Duration of macrolide
exposure, mo
Antibiotic therapy for M. abscessus subsp. abscessus
lung disease
Macrolide  i.v. antibioticsc  FQ  DOX  CFZ 10 (77) 25.5 (9.3–45.0)
Antibiotic therapy for other NTM lung disease
Macrolide  RIF  EMBd 2 (15) 17.0 (NA)
Macrolide  i.v. antibioticse 1 (8) 11.0 (NA)
Total 13 (100) 19.0 (10.5–42.5)
aThe total number of patients in the study was 13. Abbreviations: i.v., intravenous; FQ, ﬂuoroquinolone; DOX,
doxycycline; CFZ, clofazimine; NTM, nontuberculous mycobacteria; RIF, rifampin; EMB, ethambutol; NA, not
available.
bData are presented as number (percent) or as median (interquartile range).
cIntravenous antibiotics included amikacin and cefoxitin (or imipenem).
dCombination antibiotic therapy for M. avium complex lung disease.
eCombination antibiotic therapy for M. abscessus subsp. massiliense lung disease.
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antibiotic therapy for MAC infection, and another patient stopped receiving antibiotic
therapy for M. abscessus subsp. abscessus lung disease after detection of macrolide
resistance due to drug side effects. Another 11 (85%) patients received antibiotic
therapy for macrolide-resistant M. abscessus subsp. abscessus lung disease. After de-
tection of macrolide resistance, macrolides continued to be prescribed for all patients.
Intravenous (i.v.) amikacin (n 6 [46%]), i.v. cefoxitin or imipenem (n 6 [46%]), an oral
ﬂuoroquinolone (n  1 [8%]), or clofazimine (n  10 [77%]) and amikacin inhalation
(n  7 [54%]) were used at the discretion of the attending physicians. The median
duration of antibiotic therapy after detection of macrolide resistance was 24.0 months
(IQR, 16.0 to 43.0 months). Two (15%) patients underwent surgical resections, consist-
ing of lobectomy and wedge resection of another lobe at 6.9 months for one patient
and pneumonectomy at 6.5 months for the second patient, after the detection of
macrolide resistance.
Based on the occurrence and timing of sputum culture conversion (see Materials
and Methods), no patient achieved a favorable outcome after antibiotic treatment
alone. Sputum culture conversion was achieved only by the patient who had under-
gone surgical resection of the left upper lobe, with the conversion occurring subse-
quent to surgery. During the median follow-up period of 35.4 months (IQR, 13.8 to 59.9
months), two (15%) patients died, one at 3 months and the other at 8 months after the
detection of macrolide resistance.
Genetic analysis of macrolide-resistant M. abscessus subsp. abscessus isolates.
M. abscessus subsp. abscessus isolates were available from all patients for genetic
analysis, and all isolates had very high clarithromycin MICs (64 g/ml) at day 3 of DST.
All M. abscessus subsp. abscessus isolates showed rrl mutations at position 2058 (10/13
[77%]) or 2059 (3/13 [23%]), with mutations of adenine to guanine (7/13 [54%]),
adenine to cytosine (5/13 [38%]), or adenine to thymine (1/13 [8%]) (Table 4). The rrl
genotypes were 100% concordant with antibiotic susceptibility testing phenotypes,
and the 13 isolates with rrl mutations were clarithromycin resistant. Eleven isolates
contained the T28 sequevar of the erm(41) gene, whereas the other two isolates
contained the erm(41) C28 sequevar. The characteristics of the M. abscessus subsp.
abscessus isolates from the 13 patients after the development of macrolide resistance
are summarized in Table 5.
DISCUSSION
This is the ﬁrst study to investigate the detailed clinical characteristics and treatment
outcomes of patients with acquired macrolide-resistant M. abscessus subsp. abscessus
lung disease, as well as the molecular characteristics of the disease isolates. Overall, the
treatment outcome was very poor, with limited effective treatment options. Of 13
TABLE 3 Treatment modalities and outcomes after detection of macrolide-resistant M.
abscessus subsp. abscessus lung diseasea,b
Treatment modality Value
Antibiotic therapy
Amikacin 6 (46)
Cefoxitin or imipenem 6 (46)
Macrolide 11 (85)
Fluoroquinolone 1 (8)
Clofazimine 10 (77)
Amikacin inhalation 7 (54)
Surgical resection 2 (15)
Total treatment duration, mo 24.0 (16.0–43.0)
Treatment outcome
Favorable outcome 0
Sputum culture conversion after surgery 1 (8)
aThe total number of patients in the study was 13.
bData are presented as number (percent) or as median (interquartile range).
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patients, only one (8%) achieved sputum culture conversion, which occurred after
surgical resection. During the median follow-up period of 35.4 months after detection
of macrolide resistance, two (15%) patients died.
Macrolide resistance in M. abscessus subsp. abscessus can be intrinsic or acquired
depending on the resistance mechanism. Intrinsic macrolide resistance is associated
with inducible resistance, involving the presence of a functional erm(41) gene, which
encodes a type of methyltransferase known to methylate 23S rRNA (14). Acquired
macrolide resistance involves spontaneous mutations in the rrl gene, which encodes
23S rRNA, that are selected during macrolide-containing antibiotic therapy (15).
Whereas M. abscessus subsp. abscessus strains with inducible macrolide resistance show
low MICs at day 3 and require longer incubation times (up to 14 days) for the induction
of resistance, M. abscessus subsp. abscessus strains with acquired macrolide resistance
show high MICs by day 3 (21).
Treatment success rates after antibiotic therapy for M. abscessus subsp. abscessus
lung disease are less than 50% (9–13), and these low rates are attributed to inducible
macrolide resistance associated with erm(41) or to the acquisition of resistance due to
rrl mutations. Although many previous studies have reported on inducible macrolide
resistance in M. abscessus subsp. abscessus (9–13), very few studies have evaluated
acquired macrolide resistance in M. abscessus subsp. abscessus (17–19). Clinically ac-
quired mutational resistance in M. abscessus subsp. abscessus occurs relatively infre-
quently (17). In our previous study, acquired macrolide resistance associated with rrl
gene mutations developed in only 13% of patients who had persistently positive
sputum cultures after more than 12 months of antibiotic therapy (12). Recently, Maurer
et al. reported the acquisition of macrolide resistance in M. abscessus subsp. abscessus
isolates in three of ﬁve patients with chronic M. abscessus subsp. abscessus lung disease
who received long-term macrolide antibiotic therapy (18). In addition, Rubio et al.
reported that on follow-up, three patients who initially had M. abscessus subsp.
abscessus strains with the wild-type rrl sequence eventually developed acquired mac-
rolide resistance (19). In those studies, acquired macrolide resistance was associated
with macrolide resistance mutations in the 23S rRNA gene, which occurred regardless
of the presence of an inducible erm(41) methylase. However, detailed clinical charac-
teristics and long-term prognoses were not available in the previous studies.
In the present study, acquired macrolide resistance was detected during antibiotic
therapy for M. abscessus subsp. abscessus lung disease in 10 patients (10/13 [77%]).
After an intensive phase of combination i.v. antibiotic therapy for M. abscessus subsp.
abscessus lung disease, the continuation phase usually consists of oral antibiotics such
as macrolides, ﬂuoroquinolones, and doxycycline, as described in our previous studies
TABLE 4 Genetic analysis of macrolide-resistant M. abscessus clinical isolates
Mutation or sequevar No. (%) of patients with mutationa
Presence of point mutation in rrlb 13 (100)
Adenine ¡ guanine 7 (54)
A2058G 4
A2059G 3
Adenine ¡ cytosine 5 (38)
A2058C 5
A2059C 0
Adenine ¡ thymine 1 (8)
A2058T 1
A2059T 0
28th sequevar of erm(41)c
T28 11 (85)
C28 2 (15)
aThe total number of patients in the study was 13.
bNucleotides 2058 and 2059 (Escherichia coli numbering) of rrl, for which the wild-type sequence is AA. A,
adenine; G, guanine; C, cytosine; T, thymine.
cNumbering system of erm(41), with the GTG start codon as 1.
Acquired Macrolide-Resistant M. abscessus Lung Disease Antimicrobial Agents and Chemotherapy
October 2017 Volume 61 Issue 10 e01146-17 aac.asm.org 5
TABLE 5 Characteristics of isolates from the 13 patients studied
Patient Isolate
No. of mo since
ﬁrst isolatea DSTb
MIC, g/ml
(day 3/day 14)c
Colony
morphotyped erm(41)e rrlf
01 01-1 0 R 64 Mixed (R) T28 GA
Mixed (S) T28 AA
02 02-1 0 R 64 Mixed (R) T28 AA
Mixed (S) T28 CA
02-2 16 R 64 S T28 CA
03 03-1 0 R 64 S T28 AG
04 04-1 0 R 64 R T28 CA
05 05-1 0 R 64 R C28 GA
05-2 4 R 64 R C28 GA
05-3 6 R 64 R C28 GA
05-4 8 R 64 R C28 GA
05-5 11 R 64 R C28 GA
05-6 19 R 64 R C28 GA
05-7 25 R 64 R C28 GA
05-8 31 R 64 S C28 GA
06 06-1 0 R 64 S C28 CA
06-2 6 R 64 S C28 CA
06-3 10 R 64 Mixed (R) C28 CA
Mixed (S) C28 CA
07 07-1 0 R 64 R T28 TA
07-2 3 R 64 R T28 GA
07-3 5 R 64 R T28 GA
07-4 7 R 64 R T28 GA
07-5 14 R 64 R T28 GA
08 08-1 0 R 64 R T28 CA
08-2 8 R 64 R T28 CA
08-3 9 R 64 R T28 CA
08-4 13 R 64 R T28 CA
09 09-1 0 R 64 Mixed (R) T28 CA
Mixed (S) T28 CA
09-2 2 R 64 Mixed (R) T28 CA
Mixed (S) T28 CA
09-3 4 R 64 Mixed (R) T28 CA
Mixed (S) T28 CA
10 10-1 0 R 64 R T28 AG
10-2 2 R 64 Mixed (R) T28 AG
Mixed (S) T28 AG
11 11-1 0 R 64 R T28 GA
11-2 1 R 32 R T28 GA
12 12-1 0 R 64 R T28 AG
12-2 1 R 64 S T28 CA
12-3 5 R 64 S T28 CA
12-4 15 R 64 S T28 CA
12-5 18 R 64 S T28 CA
13 13-1 0 R 64 R T28 GA
13-2 2 R 64 R T28 CA
13-3 7 R 64 R T28 CA
aThe ﬁrst isolate was a clinical isolate that was ﬁrstly conﬁrmed to be resistant to macrolide on DST.
bFor DST: R, resistance.
cThe microdilution method was used to determine the MIC for clarithromycin.
dFor colony morphotype: S, smooth; R, rough.
eNumbering system of erm(41), with the GTG start codon as 1.
fNucleotides 2058 and 2059 (E. coli numbering) of rrl, for which the wild-type sequence is AA. A, adenine; G,
guanine; C, cytosine; T, thymine.
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(9, 12, 22). Our current study showed that acquired macrolide resistance can occur in
M. abscessus subsp. abscessus lung disease after macrolide monotherapy or weak
macrolide-containing antibiotic regimens, consistent with previous ﬁndings (17). To
prevent mutational macrolide resistance, a stronger regimen should be considered at
the outset for treatment of M. abscessus subsp. abscessus lung disease. Such a regimen
might include the recently proposed clofazimine or inhaled amikacin (4, 20, 23, 24),
which we administered to some of our patients following the identiﬁcation of acquired
macrolide resistance.
In our study, acquired macrolide resistance was detected during antibiotic therapy
for other NTM lung diseases in three patients (3/13 [23%]), with two cases of MAC and
one case of M. abscessus subsp. massiliense lung disease. It is not uncommon to isolate
M. abscessus subsp. abscessus during treatment of MAC lung disease, and microbiologic
and clinical follow-up is important to determine the signiﬁcance of M. abscessus subsp.
abscessus isolation in such cases (25). As MAC treatment usually consists of macrolide,
rifampin, and ethambutol, M. abscessus subsp. abscessus infection during MAC treat-
ment could result in exposure to macrolide monotherapy for M. abscessus subsp.
abscessus because neither rifampin nor ethambutol is effective in M. abscessus subsp.
abscessus infection (26, 27). Macrolide-resistant M. abscessus subsp. abscessus lung
disease also developed during antibiotic treatment of M. abscessus subsp. massiliense
lung disease in one of our patients. An oral macrolide can be effective in the contin-
uation phase of treatment of M. abscessus subsp. massiliense lung disease (28), but this
raises the possibility that new infections with M. abscessus subsp. abscessus may be
exposed to this monotherapy and acquire macrolide resistance.
In M. abscessus subsp. abscessus lung disease, the rates of achieving negative
sputum culture conversion were reported as only 25 to 42% (9–13). In this study, no
patients with acquired macrolide-resistant M. abscessus subsp. abscessus lung disease
showed negative sputum culture conversion after antibiotic therapy alone, even after
use of oral clofazimine and/or inhaled amikacin, which was reported to have clinical
efﬁcacy in patients with refractory M. abscessus subsp. abscessus lung disease (20, 23,
24). This implies that M. abscessus subsp. abscessus lung disease might be much more
difﬁcult to treat after acquisition of acquired macrolide resistance, regardless of intrinsic
inducible macrolide resistance. Further research is needed to establish optimal treat-
ment regimens for macrolide-resistant M. abscessus subsp. abscessus lung disease.
During macrolide-based antibiotic treatment, M. abscessus subsp. abscessus can
develop acquired macrolide resistance through point mutations at position 2058 or
2059 in rrl (15, 16, 18). Mutations at these positions were found in the M. abscessus
subsp. abscessus isolates of all patients in the present study, with the isolates resistant
to clarithromycin at a high level (MICs of 64 g/ml at day 3). The frequencies of
mutations at position 2058 or 2059 differ between studies. Some studies showed that
the majority of mutational changes involved A2059 (17, 29), whereas other studies
found that most mutations involved A2058 (18, 30). In our study, 23% involved A2059,
with the remaining 77% involving A2058, and there was no difference in clarithromycin
MICs based on mutation position, although only small numbers of isolates were
studied.
Acquired resistance occurs not only in M. abscessus subsp. abscessus with the
macrolide-susceptible erm(41) C28 sequevar but also in M. abscessus subsp. abscessus
with the intrinsically macrolide-resistant erm(41) T28 sequevar (15, 18, 19, 30, 31). In our
study, of the 13 isolates with rrl mutations, 85% had the T28 sequevar and 15% had the
C28 sequevar of erm(41). A recent study of mutants selected in vitro for acquired
macrolide resistance found that only 19% of mutants derived from the T28 sequevar
had rrl mutations, whereas 100% of mutants derived from the C28 sequevar had rrl
mutations (29). In clinical isolates, rrl mutations were observed more frequently in
isolates of the T28 sequevar than in isolates of the C28 sequevar (18, 30). If macrolide
treatment pressure continues, M. abscessus subsp. abscessus is likely to develop a stable
resistant lineage. Notably, none of the resistance-conferring mutations in rrl was found
to affect bacterial ﬁtness to a major degree; although the A2059G mutation demon-
Acquired Macrolide-Resistant M. abscessus Lung Disease Antimicrobial Agents and Chemotherapy
October 2017 Volume 61 Issue 10 e01146-17 aac.asm.org 7
strated a small but signiﬁcant ﬁtness cost (2.4 to 2.6% per generation), the A2058G
mutation had a nonsigniﬁcant cost (0.5 to 1.4% per generation) (32). Nevertheless, the
existence of the inducible erm(41) gene suggests that acquisition of an rrl mutation
confers some bioﬁtness disadvantage in the absence of macrolide antibiotics.
Our study has several limitations. First, it was conducted at a single referral center
and included a small number of patients. Second, treatment regimens were chosen at
the discretion of attending physicians, without an established institutional protocol.
Further studies with a larger number of patients are needed to evaluate the efﬁcacy of
antibiotic therapy in treating macrolide-resistant M. abscessus subsp. abscessus lung
disease.
In conclusion, we found that acquired macrolide resistance can develop in patients
with M. abscessus subsp. abscessus lung disease after macrolide monotherapy or with
weak antibiotic regimens in the continuation phase after initiation phases that include
multiple intravenous antibiotics. Treatment outcomes are poor after the development
of macrolide resistance, and therefore, prevention of macrolide resistance is important,
with more effective therapies needed to treat M. abscessus subsp. abscessus lung
disease both before and after the development of macrolide resistance.
MATERIALS AND METHODS
Study population. We reviewed the medical records for all patients who had macrolide-resistant M.
abscessus subsp. abscessus lung disease between November 2006 and March 2016, as identiﬁed from the
NTM Registry of Samsung Medical Center (a 1,979-bed referral hospital in Seoul, South Korea) (12). All
patients fulﬁlled the diagnostic criteria of NTM lung disease (3). This retrospective study was approved
by the institutional review board (IRB) of Samsung Medical Center (IRB application no. 2016-07-137).
Patient information was anonymized and deidentiﬁed prior to analysis; therefore, requirements for
informed consent were waived.
Radiographic and microbiologic examination. Chest radiography and high-resolution computed
tomography (HRCT) were available at the time of detection of acquired macrolide-resistant M. abscessus
subsp. abscessus in all patients. The ﬁbrocavitary form of the disease (previously called the upper lobe
cavitary form) was deﬁned by the presence of cavitary opacities mainly in the upper lobes. The nodular
bronchiectatic form was deﬁned by the presence of bronchiectasis and multiple nodules on chest HRCT,
regardless of the presence of small cavities in the lungs (12, 33).
Sputum acid-fast bacillius(AFB) smears and cultures were obtained using standard methods (34). M.
abscessus subsp. abscessus was identiﬁed and differentiated from M. abscessus subsp. massiliense and M.
abscessus subsp. bolletii by a PCR and restriction fragment length polymorphism method based on the
rpoB gene or by reverse blot hybridization assay of the rpoB gene (9, 12, 28), followed by multilocus
sequencing analysis of rrs, hsp65, and rpoB (35). Each isolate was also genotyped with regard to the
presence of a T-to-C mutation at position 28 of the erm(41) gene, as the C28 polymorphism abrogates
inducible resistance (15).
DST was performed at the Korean Institute of Tuberculosis using a broth microdilution method (21).
The MIC of clarithromycin was determined at days 3 and 14 after incubation; M. abscessus subsp.
abscessus isolates were considered susceptible (MIC  2 g/ml at days 3 and 14), resistant (MIC  8
g/ml at day 3), or inducibly resistant (susceptible at day 3 but resistant at day 14) to clarithromycin (21).
MICs for azithromycin were not determined, as clarithromycin is the class drug for macrolides (21).
Once macrolide resistance was detected, M. abscessus subsp. abscessus isolates were stored at80°C
for further analysis. To detect point mutations at position 2058 or 2059 (Escherichia coli numbering) in
the 23S rRNA gene, PCR was performed to amplify the region corresponding to domain V of the 23S rRNA
gene, according to a method described previously (36). Primers 23SF1 and 23SRIII were used for PCR and
sequencing (36).
Antibiotic therapy and treatment outcomes. Although the initial treatment regimens for M.
abscessus subsp. abscessus lung disease are standardized at our institution (9, 12, 22), treatment regimens
for macrolide-resistant M. abscessus subsp. abscessus lung disease were not standardized during the
study period. Patients with mild symptoms at the time macrolide resistance was detected received oral
antibiotics at the outpatient clinic. Patients with severe symptoms were hospitalized and received
intravenous (i.v.) amikacin (15 mg/kg [of body weight]/day in two divided doses or 15 mg/kg/day with
adjustment of a once-daily dose to target peak serum drug level of 55 to 65 g/ml), plus cefoxitin (200
mg/kg/day; maximum of 12 g/day in three divided doses) or imipenem (750 mg three times per day) for
2 to 4 weeks (9, 12, 22), along with oral antibiotics. For oral antibiotics, treatment with a macrolide
(clarithromycin at 1,000 mg/day or azithromycin at 250 mg/day) was continued, and additional drugs,
such as a ﬂuoroquinolone (ciproﬂoxacin at 1,000 mg/day or moxiﬂoxacin at 400 mg/day), clofazimine
(100 mg/day), or inhaled amikacin (250 to 500 mg/day), were used at the discretion of the attending
physicians.
Treatment outcomes were assessed by sputum culture conversion after the detection of macrolide-
resistant M. abscessus subsp.abscessus lung disease; conversion was deﬁned as three consecutive
negative cultures, with the time of conversion deﬁned as the date of the ﬁrst negative culture (9, 12). A
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favorable outcome was deﬁned as sputum culture conversion within 12 months after treatment initiation
and maintenance for 12 months with treatment.
Statistical analysis. Data are presented as the median and interquartile range (IQR) for continuous
variables and as frequency (percentage) for categorical variables. All statistical analyses were performed
using SPSS Statistics for Windows, version 23.0 (IBM, Armonk, NY).
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